Saddle Nose & Septal Perforation Associated with Chemotherapy in Patients with Acute Leukemia.
- Author:
Hyun Ung KIM
1
;
Hyoung Jin MOON
;
Woo Ick YANG
;
Joo Heon YOON
Author Information
1. Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Saddle nose;
Septal perforation;
Chemotherapy;
Acute leukemia
- MeSH:
Biopsy;
Congenital Abnormalities;
Cytarabine;
Diagnosis;
Drug Therapy*;
Epistaxis;
Humans;
Leukemia*;
Nasal Obstruction;
Nasal Septal Perforation;
Nose*;
Retrospective Studies
- From:Korean Journal of Otolaryngology - Head and Neck Surgery
2001;44(7):768-771
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
To date, no cases of nasal septal perforation during or after chemotherapy in patients with acute leukemia have been reported. In this study, we report three acute leukemia patients that had septal perforation and saddle nose deformity after chemotherapy and the results of our attempts to determine the causes of this phenomenon. We investigated retrospectively the types of chemotherapeutic agents involved and the duration of chemotherapy until the development of the nasal septal perforation. In addition, we also studied whether there were any remaining malignant cells by biopsy from the septal perforation margin. We found that Ara-C was the only drug that was used in all 3 patients. Nasal septal perforation and saddle nose developed approximately 4~7 weeks after the chemotherapy. A biopsy revealed inflammatory cells but no malignant cell infiltration. In cases of saddle nose associated with septal perforation after the chemotherapy for acute leukemia, one may consider the possibility of side effects of Ara-C. Furthermore, more active diagnosis and treatment are required when patients with acute leukemia complain of epistaxis or nasal obstruction during or after chemotherapy.
